Accelerating the development of new medicines relies on discovering better drug targets.
Getting there means finding the biological components - or true signals - of disease. Sequence Bio was founded on the belief that Newfoundland and Labrador is the best place to look.
Better target discovery starts with the right systems biology approach, enabled by an integrated stack of founder population multi-omics, real-world patient data, and well-characterized phenotypes.
The ability to create powered discovery cohorts for common and rare disease indications is not available everywhere, but it is in Newfoundland and Labrador.
Our platform is where systems biology and data-driven computation meet to identify the true signals of disease.
See how we’re working with leading pharma and biotech to shorten R&D timelines with custom discovery cohorts.
Sequence Bio’s NL Genome Project is researching the genetic makeup of 10,000 volunteering participants in Newfoundland and Labrador. By studying our province’s one-of-a-kind DNA and health information, we hope to discover better, safer medicines and improve how we treat and prevent diseases.
We’re a committed team of more than 50 local and global experts united in our mission to help improve health outcomes with better medicines, faster.
We're hiring, join the team
Sequence Bio is conducting research in Newfoundland and Labrador, and doing so in an ethical way is our first priority. Our research efforts require approval by the Health Research Ethics Board (HREB), and the words “believe,” “expect,” “anticipate,” and similar expressions, among others, generally identify our intent and/or objective to undertake additional research in this province.
Sequence Bio does not share information about planned research studies until they are approved.